Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ExCellThera and Astellas Enters into a License for the Use of Molecule UM171 in the Field of Pluripotent Stem Cells

07/13/2021 | 08:05am EDT

ExCellThera Inc. announced that it has entered into a licensing agreement with Astellas Pharma Inc. through its US subsidiary, Astellas Institute for Regenerative Medicine, for the in vitro use of the UM171 compound and certain other molecules in the field of pluripotent stem cells (PSCs) and PSC-derived cells. Under the terms of the exclusive license agreement, Astellas will pay ExCellThera an upfront payment, future contingent payments and manufacturing and supply fees for the licensed molecules.


ę S&P Capital IQ 2021
All news about ASTELLAS PHARMA INC.
01:12aASTELLAS PHARMA : to Present Fezolinetant 12-Week Findings from Phase 3 SKYLIGHT 2™ ..
PU
09/21ASTELLAS PHARMA : Science-based Exercise at Home with Fit-eNce HomeTM Pilot Sales Begins T..
PU
09/20ASTELLAS PHARMA : ' and Pfizer's XTANDI« (enzalutamide) Reduced Risk of Death by 34% in Me..
PU
09/20ASTELLAS PHARMA : ' and pfizer's xtandi (enzalutamide) reduced risk of death by 34% in men..
AQ
09/09ASTELLAS PHARMA : Updates “Contact for Potential Acquisition of ' R&D Programs&rdquo..
PU
09/02ASTELLAS PHARMA : Nitto, and M. Heart Partnering for ECG testing service
PU
09/01Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with X-linked My..
CI
08/31ASTELLAS PHARMA : Announces Personnel Changes
PU
08/30ASTELLAS PHARMA : Launches its Corporate Website's New Modalities~Approach for Cell..
PU
08/20SECTOR UPDATE : Health Care Stocks Mixed Premarket Friday
MT
More news
Financials
Sales 2022 1 325 B 12 101 M 12 101 M
Net income 2022 194 B 1 776 M 1 776 M
Net cash 2022 478 B 4 362 M 4 362 M
P/E ratio 2022 17,7x
Yield 2022 2,67%
Capitalization 3 476 B 31 819 M 31 750 M
EV / Sales 2022 2,26x
EV / Sales 2023 1,90x
Nbr of Employees 15 455
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 876,00 JPY
Average target price 2 451,54 JPY
Spread / Average Target 30,7%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Naoki Okamura CFO, Representative Director & Vice President
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.17.69%31 819
JOHNSON & JOHNSON4.54%431 227
ROCHE HOLDING AG10.52%321 941
PFIZER, INC.20.08%247 816
NOVO NORDISK A/S48.69%229 255
ELI LILLY AND COMPANY36.32%210 000